At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ABOS Acumen Pharmaceuticals, Inc.
Trading 12-22 09:54:44 EST
2.17
+0.02
+0.93%
High2.17Low2.14Vol7.44K
Open2.17D1 Closing2.15Amplitude1.40%
Mkt Cap131.44MTradable Cap71.46MTotal Shares60.57M
T/O16.11KT/O Rate0.02%Tradable Shares32.93M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

BRIEF-Acumen Pharmaceuticals Highlights Enhanced Brain Delivery Technology For Oligomer-Selective Antibodies
Reuters  ·  12-02
BRIEF-Acumen Pharmaceuticals Highlights Enhanced Brain Delivery Technology For Oligomer-Selective Antibodies
Acumen Pharmaceuticals Unveils Enhanced Brain Delivery Technology for Alzheimer’s Antibody in Phase 2 Trial
Reuters  ·  12-02
Acumen Pharmaceuticals Unveils Enhanced Brain Delivery Technology for Alzheimer’s Antibody in Phase 2 Trial
Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ Technology for Oligomer-Selective Antibodies and Recruitment Strategies for Phase 2 Altitude-Ad Clinical Trial at 18TH Annual Clinical Trials on Alzheimer’s Disease (Ctad) Conference
THOMSON REUTERS  ·  12-02
Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ Technology for Oligomer-Selective Antibodies and Recruitment Strategies for Phase 2 Altitude-Ad Clinical Trial at 18TH Annual Clinical Trials on Alzheimer’s Disease (Ctad) Conference
Acumen Pharmaceuticals Is Maintained at Buy by B of A Securities
Dow Jones  ·  11-19
Acumen Pharmaceuticals Is Maintained at Buy by B of A Securities
Acumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
GlobeNewswire  ·  11-18
Acumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Acumen Pharmaceuticals Doses First Participant in Phase 2 Extension Study of Sabirnetug for Early Alzheimer’s Disease
Reuters  ·  11-17
Acumen Pharmaceuticals Doses First Participant in Phase 2 Extension Study of Sabirnetug for Early Alzheimer’s Disease
Acumen Pharmaceuticals Inc: Acumen Expects to Report Topline Results From Altitude-Ad in Late 2026
THOMSON REUTERS  ·  11-17
Acumen Pharmaceuticals Inc: Acumen Expects to Report Topline Results From Altitude-Ad in Late 2026
Acumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People With Early Alzheimer’s Disease
THOMSON REUTERS  ·  11-17
Acumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People With Early Alzheimer’s Disease
Acumen Pharmaceuticals Inc - May Offer Common Stock up to $50 Mln - SEC Filing
THOMSON REUTERS  ·  11-13
Acumen Pharmaceuticals Inc - May Offer Common Stock up to $50 Mln - SEC Filing
Citi Sticks to Its Buy Rating for Acumen Pharmaceuticals (ABOS)
TIPRANKS  ·  11-13
Citi Sticks to Its Buy Rating for Acumen Pharmaceuticals (ABOS)
Acumen Pharmaceuticals’ Earnings Call: Progress and Challenges
TIPRANKS  ·  11-13
Acumen Pharmaceuticals’ Earnings Call: Progress and Challenges
Acumen Pharmaceuticals Unveils Sabirnetug Data Targeting Early Alzheimer’s Disease
Reuters  ·  11-12
Acumen Pharmaceuticals Unveils Sabirnetug Data Targeting Early Alzheimer’s Disease
Acumen Pharmaceuticals Reports Q3 Financial Results
TIPRANKS  ·  11-12
Acumen Pharmaceuticals Reports Q3 Financial Results
Biopharma firm Acumen's Q3 net loss narrows, beats estimates
Reuters  ·  11-12
Biopharma firm Acumen's Q3 net loss narrows, beats estimates
BRIEF-Acumen Pharmaceuticals, Inc. Q3 Income From Operations USD -26.513 Million
Reuters  ·  11-12
BRIEF-Acumen Pharmaceuticals, Inc. Q3 Income From Operations USD -26.513 Million
Acumen Pharmaceuticals Q3 EPS $(0.44) Beats $(0.58) Estimate
Benzinga  ·  11-12
Acumen Pharmaceuticals Q3 EPS $(0.44) Beats $(0.58) Estimate
Acumen Pharmaceuticals posts Q3 2025 cash balance of $136.1 million
Reuters  ·  11-12
Acumen Pharmaceuticals posts Q3 2025 cash balance of $136.1 million
Acumen Pharmaceuticals Inc: Expects Non-Clinical Data to Support Development of Ebd Therapy in Early 2026
THOMSON REUTERS  ·  11-12
Acumen Pharmaceuticals Inc: Expects Non-Clinical Data to Support Development of Ebd Therapy in Early 2026
Acumen Pharmaceuticals, Inc. Q3 Basic EPS USD -0.44
THOMSON REUTERS  ·  11-12
Acumen Pharmaceuticals, Inc. Q3 Basic EPS USD -0.44
Press Release: Acumen Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Highlights
Dow Jones  ·  11-12
Press Release: Acumen Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Highlights

Introduction

Company Name.
Acumen Pharmaceuticals, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Issue price:
--